간외담관암의 수술 후 방사선치료 성적

Treatment Outcome of Postoperative Radiotherapy in Extrahepatic Bile Duct Cancer

  • 최영민 (인제대학교 의과대학 부산백병원 방사선종양학과) ;
  • 조흥래 (인제대학교 의과대학 부산백병원 방사선종양학과)
  • Choi, Young-Min (Department of Radiation Oncology, Pusan Paik Hospital, Inje University College of Medicine) ;
  • Cho, Heung-Lae (Department of Radiation Oncology, Pusan Paik Hospital, Inje University College of Medicine)
  • 발행 : 2003.03.01

초록

목적 : 간외담관암 환자들의 수술 후 방사선치료 성적을 조사하여, 방사선치료의 역할과 생존율에 영향을 주는 인자들을 분석하고자 하였다. 대상 및 방법 : 1991년 10월부터 2001년 7월까지 간외담관암으로 근치적 절제술 후에 방사선치료를 받은 21명을 대상으로 하였다. 환자들의 연령은 39$\~$75세(중앙값 61세)였고, 남여의 비는 16:5였다. 근위부 담관암이 14명이었고, 원위부 암이 7명이었다. 수술 후 조직 검사에서 미세 병변이 19명에서 남았고, 림프절 전이가 7명에서 관찰되었다. AJCC 병기는 I, II, III 기가 각각 10, 10, 1명이었다. 총방사선량은 4,500$\~$6,300 cGy의 범위(중앙값 5,040 cGy)였고, 추적 조사 기간은 20$\~$81개월(중앙값 57.5개월)이었다 결과 : 3년, 5년 생존율이 각각 41.0$\%$, 29.3$\%$였고, 3년, 5년 무병 생존율은 각각 41.6$\%$, 29.7$\%$였다. 생존율에 영향을 주는 변수로 연령, 성별, 종온기 위치, 분화도, 수술 후 미세 병변의 잔존 유무, 신경 침범, 7 병기, N 병기, 병기, 방사선량, 화학요법 유무 등을 조사하여서, 단변량 분석에서 T 병기와 병기가 유의하였지만(p<0.05), 대상 환자의 수가 적어서 의미를 주기에는 제한이 있었다 12명(57.1$\%$)에서 재발이 발생되었는데, 국소 부위가 5명, 원격 전이가 4명, 국소 및 원격 전이가 동반된 경우가 3명이었고, 원격 전이 부위로는 간이 6명, 뼈가 1명이었다. 급성 부작용으로 2, 3도 백혈구 감소증이 각각 1명에서 발생되었고, 만성 부작용으로 2도 소화성 궤양이 4명에서 발생되었으나, 모두 보조적 치료로 회복되었다 결론 : 간외담관암 환자들에서 근치적 절제술 후의 방사선치료는 심각한 부작용의 발생 없이 적용 가능하며, 수술후 방사선치료의 효과와 예후 인자의 분석을 위해서는 보다 많은 환자들을 대상으로 전향적인 연구가 요구된다.

Purpose : To evaluate the efficacy of radiotherapy, and the factors affecting survival in patients of extrahepatic bile duct cancer, by analyzing the results of postoperative radiotherapy Materials and Methods : Between October 1991 and July 2001, 21 patients with extrahepatic bile duct cancer, who received radiotherapy after a radical resection, were retrospectively reviewed. The patients' ages ranged from 39 to 75 years, with a median of 61 years, and a male to female ratio of 16 to 5. The numbers of patients with proximal and distal bile duct cancer were 14 and 7, respectively. From the postoperative pathological examination, 19 of the patients were found to have microscopic residues, and 7 to be lymph node positive. Patients with AJCC stages I, II and III were 10, 10 and 1, respectively. The total radiation dose administered was 4,500$\~$6,300 cGy, with a median dose of 5,040 cGy. The follow up period was 20$\~$81 months, with a median of 57.5 months. Results : The overall and disease free survival rates at 3 and 5 years were 41.0 and 29.3$\%$, and 41.6 and 29.7$\%$, respectively. The influences of age, sex, tumor location, differentiation, microscopic residue, neural invasion, 7 and N stage, the stage itself, the dose of radiation and chemotherapy, on survival were evaluated. The T stage and the stage itself were found to be significant from a univariate analysis (p<0.05), but the degree of significance was limited by the small number of patients. A recurrence occurred in 12 patients (57.1$\%$), 5 in locoregional sites, 4 in distant sites and 3 in a combination of locoregional and distant sites, and the sites of distant metastasis were the liver, 6, and the bone, 1 Grade 2 or 3 acute leucopenias occurred in 2 patients and grade 2 chronic peptic ulcers occurred in 4, who were all recovered by conservative management. Conclusion : Postoperative radiotherapy is feasigbls in extrah데atic bile duct cancer, with tolerable toxicity, but prospective studies, with a large patient enrollment, are needed for the evaluation of the effects of postoperative radiotherapy and the related prognostic factors.

키워드

참고문헌

  1. Korea Central Cancer Registry. Annual report of the Korea central cancer registry program, Ministry of Health and Welfare, 2002
  2. Bosma A. Surgical pathology of cholangiocarcinoma of the liver hilus (Klatskin tumor). Semin Liver Dis 1990;10:85-90 https://doi.org/10.1055/s-2008-1040460
  3. Kopelson G, Galdabini J, Warshaw AL, Gunderson LL. Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: implications for adjuvant therapy. Int J Radiat Oncol Bioi Phys 1981;7:413-417 https://doi.org/10.1016/0360-3016(81)90118-8
  4. Okuda K, Kubo Y, Okazaki N, Arishima T, Hashimoto M. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma: a study of 57 autopsy-proven cases. Cancer 1977;39:232-246 https://doi.org/10.1002/1097-0142(197701)39:1<232::AID-CNCR2820390137>3.0.CO;2-Y
  5. Jarnagin WR, Koea JB, Klimstra DS. Cancers of the biliary tract: Staging, technique, and pathology. In: Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE, eds. Gastrointestinal oncology: Principals and practice. Philadelphia, PA: Lippincott Wiliams & Wilkins. 2002:615-643
  6. Weinbren K, Mutum SS. Pathological aspects of cholangiocarcinoma. J Pathol 1983;139:217-238 https://doi.org/10.1002/path.1711390210
  7. Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH. Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation. and a presurgical clinical staging system. Ann Surg 1998;228:385-394
  8. Pichlmayr R, Weimann A, Klempnauer J, et al. Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg 1996;224:628-638 https://doi.org/10.1097/00000658-199611000-00007
  9. Schoenthaler R, Phillips TL, Castro J, Efird JT, Better A, Way LW. Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 1994;219:267-274 https://doi.org/10.1097/00000658-199403000-00006
  10. Benjamin IS. Surgical possibilities for bile duct cancer: standard surgical treatment. Ann Oncol 1999;10(Suppl 4):239-242 https://doi.org/10.1093/annonc/10.suppl_4.S239
  11. Hadjis NS, Blenkharn JI, Alexander N, Benjamin IS, Blumgart LH. Outcome of radical surgery in hilar cholangiocarcinoma. Surgery 1990;107:597-604
  12. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463-473 https://doi.org/10.1097/00000658-199610000-00005
  13. Shimada H, Niimoto S, Matsuba A, Nakagawara G, Kobayashi M, Tsuchiya S. The infiltration of bile duct carcinoma along the bile duct wall. Int Surg 1988;73:87-90
  14. Gonzalez GD, Gerard JP, Maners AW, et al. ReSUlts of radiation therapy in carcinoma of the proximal bile duct (Klatskin tumor). Semin Liver Dis 1990;10:131-141 https://doi.org/10.1055/s-2008-1040466
  15. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, Lillemore KD, Cameron JL. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995;221:788-797 https://doi.org/10.1097/00000658-199506000-00017
  16. Kamada T, Saitou H, Takamura A, Nojima T, Okushiba SI. The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Bioi Phys 1996;34:767-774 https://doi.org/10.1016/0360-3016(95)02132-9
  17. Alden ME, Waterman FM, Topham AK, Barbot DJ, Shapiro MJ, Mohiuddin M. Cholangiocarcinoma: clinical significance of tumor location along the extrahepatic bile duct. Radiology 1995;197:511-516
  18. Nagorney DM, Donohue JH, Farnell MB, Schleck CD, IIstrup DM. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993;128:871-879 https://doi.org/10.1001/archsurg.1993.01420200045008
  19. Fong Y, Blumgart LH, Lin E, Fortner JG, Brennan MF. Outcome of treatment for distal bile duct cancer. Br J Surg 1996;83:1712-1715 https://doi.org/10.1002/bjs.1800831217
  20. Wade TP, Prasad CN, Virgo KS, Johnson FE. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. J Surg Oncol 1997;64:242-245
  21. Kraybill WG, Lee H, Picus J, et al. Multidisciplinary treatment of biliary tract cancers. J Surg Oncol 1994;55:239-245 https://doi.org/10.1002/jso.2930550408
  22. Alden ME, Mohiuddin M. The impact of radiation dose in combined eXternal beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Bioi Phys 1994; 28:945-951 https://doi.org/10.1016/0360-3016(94)90115-5
  23. Morganti AG, Trodella L, Valentini V, et al. Combined modality treatment in unresectable extrrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 2000;46:913-919 https://doi.org/10.1016/S0360-3016(99)00487-3
  24. Milella M, Salvetti M, Cerrotta A, et al. IntelVentional radiology and radiotherapy for inoperable cholangiocarcinoma of the extrahepatic bile ducts. Tumori 1998;84:467-471
  25. Bouras N, Caudry M, Saric J, et al. Conformal therapy of locally advanced cholangiocarcinoma of the main bile ducts. Cancer Radiother 2002;6:22-29 https://doi.org/10.1016/S1278-3218(01)00144-5
  26. Gonzalez GD, Gouma DJ, Rauws EA, van Gulik TM, Bosma A, Koedooder C. Role of radiotherapy, in particular intraluminal brachytherapy, in the treatment of proximal bile duct carcinoma. Ann Oncol 1999;10(Suppl 4):215-220 https://doi.org/10.1093/annonc/10.suppl_4.S215
  27. Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology 2000;47:644-649
  28. Smith GW, Bukowski RM, Hewlett JS, Groppe CWo Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma. Cancer 1984; 54:1513-1516
  29. Kemeny N, Daly J, Reichman B, Geller N, Botel J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987;107: 459-465 https://doi.org/10.7326/0003-4819-107-4-459